Nasdaq
$11.79▼ 0.59%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $244.2MShares out 20.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 8.27After-hours26.08.28 07:56SCHEDULE 13D/AOwnership#●●●#●●●
AMARIN CORP PLC\UKBullish
A major shareholder of Amarin (AMRN) executed a large-scale sale of their stake over two days, from August 24 to August 25, 2026. During this period, hundreds of thousands of ADSs were sold in the market at prices ranging from $14.00 to $14.08 per share.…more
$11.79-0.59%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.3After-hours26.08.04 05:304Ownership
AMARIN CORP PLC\UK
아마린(AMRN)의 내부자 피터 L. 피시먼(Peter L. Fishman)이 2026년 8월 1일자로 주식 소유권 변동 사항을 보고하는 Form 4 공시를 제출하였습니다. 해당 공시는 내부자의 지분 보유 현황 변경을 공식화한 문서입니다.…more
$11.79-0.59%vs prev closeView filingShare - 7.29After-hours26.07.30 05:3010-QEarnings
AMARIN CORP PLC\UK
아마린(Amarin)은 2026년 6월 18일 이사회 보상 정책을 개정하여 주주들의 우선매수권 포기 승인 실패에 따라 비임원 이사들에게 주식 보상 대신 17만 5천 달러의 제한적 현금 보상을 지급하기로 확정했습니다. 또한 2026년 2분기 실적 보고를 통해 재무 상태와 운영 현황을 공시하며 경영진의 내부 통제 및 재무 보고 책임에 대한 인증을 완료했습니다.…more
$11.79-0.59%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 13m agoClosed26.10.25 21:11#●●●#●●●
Amarin Reports Mixed Phase 3 Results for VAZKEPA in Colorectal Cancer Liver Metastases…more
Amarin's VAZKEPA failed to meet the primary endpoint of progression-free survival in a Phase 3 trial for colorectal cancer liver metastases, though it showed a statistically significant improvement in overall survival. The company plans to conduct further evaluations to explore the potential therapeutic role of the drug in this patient population.…more
$11.79-0.59%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 4d agoPre-market26.10.21 21:00
●●●●●●●● ●●●●● ●●●●●●
Amarin Corporation announced that it will release its third quarter 2026 financial results and host a conference call on October 28, 2026. The event will provide investors with an update on the company's quarterly performance and operational progress.…more
$11.79-0.59%vs prev close - 8.31Pre-market26.08.31 21:15
●●●●●●●● ●●●●● ●●●●●●
Amarin highlighted new research and mechanistic data for its cardiovascular drug at the European Society of Cardiology Congress. While the findings reinforce the clinical evidence supporting the treatment, they do not represent new commercial contracts or financial growth.…more
$11.79-0.59%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report